ART FAIR: October is art fair season in London, bringing members of the industry from all over the globe to the capital. The ...

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed. The above button links to ...

Forbes contributors publish independent expert analyses and insights. Robert Glatter is a New York-based physician covering public health. This voice experience is generated by AI. Learn more. This ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Please provide your email address to receive an email when new articles are posted on . Pelacarsen did not reduce cardiovascular events in patients with elevated lipoprotein(a) compared with placebo.

The much-anticipated Lp(a)HORIZON trial testing whether the novel drug pelacarsen can improve cardiovascular outcomes by decreasing lipoprotein(a) levels has failed to meet its primary endpoint.

Daniel Jassy, CFA, is an Investopedia Academy instructor and the founder of SPYderCRusher Research. He contributes to Excel and Algorithmic Trading. Dr. JeFreda R. Brown is a financial consultant, ...

Pete Rathburn is a copy editor and fact-checker with expertise in economics and personal finance and over twenty years of experience in the classroom. Present value of a bond is the sum of all future ...

The result calls into question other late-stage trials testing Lp(a)-lowering drugs from the likes of Amgen and Eli Lilly. (iStock / Getty Images Plus) Novartis’ Ionis-partnered drug designed to lower ...

Novartis’ pelacarsen failed to reduce cardiovascular events despite lowering the harmful cholesterol Lp(a). The setback raises uncertainty for rival experimental Lp(a) drugs from Amgen and Eli Lilly.

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner Novartis today announced that the pelacarsen Phase 3 Lp(a)HORIZON study, a pioneering cardiovascular outcomes ...

While Windows users are disappointingly familiar with updates causing problems, the same cannot be said of people using Microsoft Office. But with the release of the KB5002914 update for Excel, ...